Eczema future or investigational therapies

Eczema Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eczema from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Social Impact

Future or Investigational Therapies

Case Studies

Case #1

Eczema On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eczema

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eczema

CDC on Eczema

Eczema in the news

Blogs on Eczema

Directions to Hospitals Treating Eczema

Risk calculators and risk factors for Eczema

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief:  Edzel Lorraine Co, D.M.D., M.D.

## Overview

[edit | edit source]

Future trends will focus more on genetic studies in eczema. [1]

## Eczema Future or Investigational Therapies

[edit | edit source]

* Future trends will focus more on genetic studies in eczema.
* These genetic discoveries can be applied to the development of new drugs that can target the molecular and physiological causes of the disease, making an era of "personalized medicine". [2]
* Digitalization and artificial intelligence can also be applied to the management of eczema. [3]

## References

[edit | edit source]

1. ↑ Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S; et al. (2012). "Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect". J Invest Dermatol. 132 (1): 98–104. doi:10.1038/jid.2011.342. PMC 3236450. PMID 22071473.CS1 maint: Multiple names: authors list (link)
2. ↑ Dugger SA, Platt A, Goldstein DB (2018). "Drug development in the era of precision medicine". Nat Rev Drug Discov. 17 (3): 183–196. doi:10.1038/nrd.2017.226. PMC 6287751. PMID 29217837.CS1 maint: Multiple names: authors list (link)
3. ↑ Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M; et al. (2020). "ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children". J Eur Acad Dermatol Venereol. 34 (12): 2717–2744. doi:10.1111/jdv.16892. PMID 33205485 Check `|pmid=` value (help).CS1 maint: Multiple names: authors list (link)